5-HT1B/1D receptor agonist (triptan)

Eletriptan

Cranial vasoconstriction and inhibition of trigeminal neuropeptide release via 5-HT1B and 5-HT1D receptors.

NeurologicalVascularReceptor agonism

Primary Mechanism of Action

Clinical / Scientific

Eletriptan agonizes 5-HT1B receptors on cranial vessels (vasoconstriction) and 5-HT1D receptors on trigeminal terminals (reduced CGRP and other peptide release), interrupting migraine signalling.

Pathway Targets

5-HT1B

Scientific explanation

Cranial vascular smooth-muscle constriction.

5-HT1D

Scientific explanation

Inhibition of trigeminal peptide release.

Pathway Convergence

Clinical / Scientific

Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.

Trigeminovascular quieting

Target to downstream effect: 5-HT1B/1D agonism → Cranial vasoconstriction + reduced CGRP release → Attenuation of migraine signalling

5-HT1B/1D agonism
↓
Cranial vasoconstriction + reduced CGRP release
↓
Attenuation of migraine signalling

Mechanistically Relevant Repurposed & Adjunctive Applications

Acute migraine

Established

Mechanistic rationale

Established triptan for labelled acute migraine treatment.

Mechanistic Application Matrix

Biological TargetMechanismPotential RelevanceEvidence Level
5-HT1BAgonismCranial vasomotor toneEstablished mechanism
5-HT1DAgonismTrigeminal neuropeptide releaseEstablished mechanism

Mechanistic Interaction Considerations

Do not combine with other serotonergic antimigraine agents (ergots, other triptans) within labelled windows. Coronary disease and uncontrolled hypertension are class contraindications. -syndrome risk with some antidepressants is labelled.

In Plain Language

During migraine, pain nerves around brain blood vessels release peptides and vessels change calibre. Eletriptan stimulates receptors that tighten those vessels slightly and tell the nerves to release fewer peptides.

Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.